HSP-based pharmacological interventions have been considered for Alzheimer’s, Parkinson’s, Huntington’s, and ALS [39,40,41,42,43], with the aim of correcting chaperone dysfunction, restoring proteostasis [44]. Here, HSP90B2P is linked to amyotrophic lateral sclerosis.